GIC-Backed WCG Clinical Plans $100M NASDAQ Debut - Renaissance IPO ETF (ARCA:IPO), First Trust US Equity Opportunities ETF (ARCA:FPX)

WCG Clinical Inc WCGC, a clinical trial solutions company backed by Singapore's sovereign wealth fund GIC, filed for an initial public offering in the U.S. on Thursday to trade on NASDAQ under the "WCGC" symbol.
Private equity firms Arsenal Capital Partners and Leonard Green & Partners LP are also investors in the firm, which helps clients reduce the time and cost of enrolling patients in clinical trials.
Launched back in 2012, WCG Clinical Services claims to have supported around 90% of global clinical trials that took place over the last two years, providing services like study planning, patient engagement, and ethical review.
The team participated in more than 723 Covid-19 trials, according to CEO Donald Deieso.
"We firmly believe that we must have the clinical insight to develop, the courage to advance, and the persistence to transform a change-resistant industry while never compromising the highest level of ethical standards," Deieso said in the S-1.